Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1316 Neoplasms 1104 Carcinoma, Non-Small-Cell Lung 916 Prostatic Neoplasms 747 Colorectal Neoplasms 645 Lung Neoplasms 621 Neoplasm Metastasis 470 Multiple Myeloma 444 Leukemia, Myeloid, Acute 440 Pancreatic Neoplasms 392 Ovarian Neoplasms 388 Melanoma 346 Carcinoma, Hepatocellular 308 Brain Neoplasms 290 Squamous Cell Carcinoma of Head and Neck 285 Recurrence 285 Glioblastoma 260 Stomach Neoplasms 252 Head and Neck Neoplasms 250 Precursor Cell Lymphoblastic Leukemia-Lymphoma 238 Carcinoma, Renal Cell 237 Lymphoma 235 Triple Negative Breast Neoplasms 233 Endometrial Neoplasms 221 Uterine Cervical Neoplasms 217 Hematologic Neoplasms 216 Urinary Bladder Neoplasms 212 Lymphoma, Non-Hodgkin 203 Glioma 202 Sarcoma 200

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 enfortumab vedotin 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × 90 days × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡